LYMPHOID NEOPLASIA Progression in smoldering Waldenström macroglobulinemia: long-term results
نویسندگان
چکیده
The purpose of this study was to define the risk of progression and survival of patients with smoldering Waldenström macroglobulinemia (SWM). SWM is defined clinically as having a serum monoclonal IgM protein > 3 g/dL and/or > 10% bone marrow lymphoplasmacytic infiltration but no evidence of end-organ damage (anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly). We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of SWM between 1974 and 1995. During 285 cumulative person-years of follow-up of the 48 patients with SWM (median, 15.4 years), 34 (71%) progressed to symptomatic Waldenström macroglobulinemia (WM) requiring treatment, one to primary amyloidosis, and one to lymphoma (total, 75%). The cumulative probability of progression to symptomatic WM, amyloidosis, or lymphoma was 6% at 1 year, 39% at 3 years, 59% at 5 years, and 68% at 10 years. The major risk factors for progression were percentage of lymphoplasmacytic cells in the bone marrow, size of the serum M-spike, and the hemoglobin value. Patients with SWM should be followed and not treated until symptomatic WM develops. Treatment on a clinical trial for those at greatest risk of progression should be considered. (Blood. 2012; 119(19):4462-4466)
منابع مشابه
LYMPHOID NEOPLASIA Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy
Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy Jia Li,1 Daniel M.-Y. Sze,1-3 Ross D. Brown,2 Mark J. Cowley,4 Warren Kaplan,4,5 Sui-Lin Mo,1,6 Shihong Yang,2 Esther Aklilu,2 Karieshma Kabani,2 Yen S. Loh,1 Tetsuo Yamagishi,1 Yuling Chen,1,5 P. Joy Ho,2 and D...
متن کاملProgression in smoldering Waldenstrom macroglobulinemia: long-term results.
The purpose of this study was to define the risk of progression and survival of patients with smoldering Waldenström macroglobulinemia (SWM). SWM is defined clinically as having a serum monoclonal IgM protein≥3 g/dL and/or≥10% bone marrow lymphoplasmacytic infiltration but no evidence of end-organ damage (anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly). ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
1Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2BioBridges, Boston, MA; 3McMaster University Medical Center, Hamilton, ON; 4University of California Los Angeles (UCLA) Medical Center; 5Greenebaum Cancer Center, University of Maryland, Baltimore; 6Medical Oncology, St Bartholomew’s Hospital and Cancer Research, London, United K...
متن کاملLYMPHOID NEOPLASIA Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation
Familial aggregation of Waldenström macroglobulinemia (WM) and related B-cell disorders (BCDs) suggests a role for genetic factors, but few data address environmental influences. We designed a questionnaire-based study to examine clinical and environmental factors in a cohort of WM families with various patterns of case aggregation. We analyzed data on 103 WM patients and 272 unaffected relativ...
متن کاملLYMPHOID NEOPLASIA Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia
Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenström macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects. Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive proteas...
متن کامل